万古霉素粉末在脊髓刺激器植入术中的作用:病例系列与文献综述
该回顾性研究分析2014至2020年153例经开放椎板切除行永久性脊髓刺激器(SCS)植入术患者,比较术中应用与未应用万古霉素粉末者术后3个月内手术部位感染(SSI)和血清肿的发生率。结果显示SSI总体2%,两组差异无统计学意义(P=0.73);血清肿均见于未用万古霉素组,差异有统计学意义(P=0.04);多因素回归未发现独立预测因素。
要点
- 开放椎板切除SCS植入术后SSI率低,用或不用万古霉素粉末均可。
- 万古霉素粉末未显示不安全或与术后血清肿形成相关。
- 本研究未能就其预防SSI的疗效得出确定性结论。
核心结论
- 开放椎板切除SCS植入手术的术后SSI率低,用或不用万古霉素粉末均可施行。
- 未发现万古霉素粉末不安全或与术后血清肿形成相关的证据。
- 尽管参考了迄今最大的SCS植入单中心病例系列,仍无法就其疗效得出确定性结论。
研究设计与样本
- 回顾性分析2014至2020年连续153例经开放椎板切除行永久性SCS植入术的患者。
- 查阅病历获取年龄、性别、相关病史及是否使用万古霉素粉末。
- 比较万古霉素组与未用万古霉素组术后3个月内SSI(主要结局)和血清肿(次要结局)发生率。
- 采用多因素logistic回归分析识别术后SSI或血清肿的独立预测因素。
主要发现
- 153例中女性占59%,平均年龄65.4岁。
- 共3例(2%)发生SSI:万古霉素组2例(耐甲氧西林金黄色葡萄球菌、克雷伯菌),未用万古霉素组1例(甲氧西林敏感金黄色葡萄球菌);两组SSI率差异无统计学意义(P=0.73)。
- 3例血清肿均见于未用万古霉素组,两组血清肿形成差异有统计学意义(P=0.04)。
- 多因素logistic回归未识别出任何围手术期特征为术后SSI或血清肿的独立预测因素。
临床怎么用
- SCS植入术中可考虑不使用万古霉素粉末,因本研究未证实其预防SSI的明确获益。
- 不应以血清肿风险为由拒绝使用万古霉素粉末,本研究中血清肿均见于未用药组。
- 术后SSI风险评估可参考本研究低感染率背景,但需结合患者具体情况个体化判断。
局限性
- 回顾性单中心病例系列,样本量有限(153例),SSI事件数少(3例)。
- 无法就万古霉素粉末预防SSI的疗效得出确定性结论。
- 多因素回归未发现独立预测因素,可能受事件数少限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined the role of intrawound vancomycin powder as prophylaxis against postoperative surgical site infection (SSI) after spinal cord stimulator (SCS) implantation. METHODS: We performed a retrospective analysis of 153 consecutive patients who had undergone permanent SCS implantation surgery via open laminectomy between 2014 and 2020. We queried the patients' medical records for patient age, sex, relevant medical history, and whether intrawound vancomycin had been administered. We compared the rates of SSI (primary outcome) and seroma (secondary outcome) within 3 months after surgery between the vancomycin and no-vancomycin groups. Finally, we conducted multivariable logistic regression analyses to identify independent predictors of postoperative SSI or seroma. RESULTS: Of the 153 patients, 59% were women, and the average age was 65.4 years. Overall, 3 patients (2%) had developed an SSI: 2 (methicillin-resistant Staphylococcus aureus, Klebsiella) in the vancomycin group and 1 (methicillin-sensitive Staphylococcus aureus) in the no-vancomycin group. This difference in SSI rate between the 2 groups was insignificant (P = 0.73). Three seromas, all in the no-vancomycin group, accounted for a statistically significant difference in seroma formation between the 2 groups (P = 0.04). Multivariate logistic regression failed to identify any perioperative characteristics as independent predictors of postoperative SSI or seroma. CONCLUSIONS: Our experience suggests open laminectomy for SCS implantation surgery can be performed with a low postoperative SSI rate, with or without the use of powdered vancomycin. We found no evidence suggesting that the use of powdered vancomycin is unsafe or related to postoperative seroma formation. We failed to draw any definitive conclusions regarding its efficacy, despite referencing the largest single case series of SCS implantation to date.
引用
- Zarrin DA, Wilson BR, Teton ZE, et al. The Role of Vancomycin Powder During Spinal Cord Stimulator Implantation: A Case Series and Review of the Literature. World Neurosurg. 2021. PMID: 34500098. doi:10.1016/j.wneu.2021.08.141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。